Latest News

MS medication withdrawn because of safety concerns


 

Citing concerns about safety, Biogen and AbbVie announced March 2 that they will be withdrawing daclizumab (Zinbryta) from worldwide markets. Daclizumab has known risks, so it was usually prescribed only for people with relapsing multiple sclerosis who had tried two or more other medications that hadn’t worked well enough.

Reports of inflammatory encephalitis and meningoencephalitis led the European Medicines Agency to initiate an Article 20 referral procedure. In such referrals, a medicine or class of medicines are scientifically assessed because of concerns over safety or quality.

However, Biogen and AbbVie concluded that, because of the complex nature of these reports and how few patients were taking daclizumab, it would be difficult to characterize the nature of the medication’s harms and benefits, so the companies instead have decided to withdraw the medication from the market.

On March 14, the Food and Drug Administration announced that it is conducting a review of similar adverse event reports it has received.

The drug will continue to be available to patients until April 30, 2018. Patients taking daclizumab should not stop taking the drug without talking to their doctor and should contact their doctor if they have any new or unexplained symptoms, the FDA said. More information can be found in the press release .

cpalmer@frontlinemedcom.com

**Story updated 3/14/2018.

Recommended Reading

ECTRIMS and EAN Publish Recommendations for Treating MS
MDedge Neurology
Does Vitamin D Level Affect Progressive MS?
MDedge Neurology
Is MS caused by one-two punch of pinworm and Epstein-Barr virus?
MDedge Neurology
Extended-interval dosing of natalizumab linked to lower risk of PML
MDedge Neurology
Fingolimod switch from an injectable linked to improved outcomes in relapsing MS
MDedge Neurology
Researchers find predictors of worse MS outcomes in post hoc study of three trials
MDedge Neurology
Health Care Use May Elucidate MS Prodrome
MDedge Neurology
How Are Newer DMTs Used in Pediatric MS?
MDedge Neurology
Can Online Patient Journals Improve MS Care?
MDedge Neurology
High dose of novel compound for relapsing-remitting MS shows promise
MDedge Neurology